Outset Medical (OM) 44th Annual J.P. Morgan Healthcare Conference summary

Company overview and market positioning

• Operates at scale in the $2.5B acute/post-acute market, with over 1,000 hospitals using its technology for about a million treatments annually.

• Has delivered over 3.5 million treatments in the U.S. and is expanding into the $8.9B home dialysis market.

• Evolved from a device company to an enterprise-level dialysis solution provider, integrating data analytics, EMR connectivity, and field support.

• 70% of total revenue is recurring, and the company entered 2026 with a strong balance sheet aimed at cash flow breakeven.

• Focuses on two of three dialysis submarkets: inpatient (acute/post-acute) and home.

Industry landscape and challenges

• Dialysis is a large, expensive, and slow-to-innovate sector, with 90 million annual treatments in the U.S. costing $71B, $55B of which is covered by Medicare.

• Most hospitals outsource dialysis, leading to unreimbursed costs, higher ICU admissions, longer stays, and increased infection and compliance risks.

• Inpatient dialysis is a pure cost center for hospitals, with losses of $5,000–$25,000 per admission involving dialysis.

• Outsourcing increases infection rates and compliance challenges, while insourcing with new technology reduces these risks.

Technology and service model innovation

• Tablo device introduced several industry firsts: on-demand water purification, real-time dialysate production, and cloud-based data transmission.

• Advanced analytics dashboard and EMR interoperability empower hospitals to benchmark and improve clinical and financial outcomes.

• Proprietary implementation services and temporary staffing support hospitals transitioning from outsourced to insourced dialysis.

• AI and machine learning initiatives aim to shift service from reactive to predictive, enhancing uptime and patient access.